A subsidiary company of Joincare Pharmaceutical Group Industry (600380.SH) has obtained the notice of approval for drug clinical trials.

Joincare Pharmaceutical Group Industry (600380.SH) announced that its subsidiary Livzon Pharmaceutical Group Inc. has received approval from the National Medical Products Administration for a new indication for NS-041 tablets, specifically for the treatment of depression. The approval allows for clinical trials to be conducted for this new indication. NS-041 is a novel, highly selective KCNQ2/3 agonist intended for the treatment of neurological and psychiatric disorders such as epilepsy and depression. It is currently the only KCNQ2/3 targeted drug approved in China for clinical trials in both epilepsy and depression. On December 27, 2023, NS-041 was approved for clinical trials for the indication of epilepsy, and it is currently in Phase II clinical studies for this indication. The recent approval for the treatment of depression expands the potential uses for NS-041 in clinical trials.